Dosing Starts in Phase 3 Trial of ALZ-801 in Patients With APOE Variant

Dosing Starts in Phase 3 Trial of ALZ-801 in Patients With APOE Variant

296687

Dosing Starts in Phase 3 Trial of ALZ-801 in Patients With APOE Variant

A first patient has been dosed in APOLLOE4, a Phase 3 trial testing the efficacy and safety of ALZ-801, an investigational oral treatment by Alzheon for people carrying a specific genetic variant linked to early onset, rapidly progressive Alzheimer’s disease. ALZ-801 is a small molecule designed to prevent the formation and clustering of harmful proteins that play a role in the development of Alzheimer’s. It does this by releasing tramiprosate, a compound that protects nerve cells…

You must be logged in to read/download the full post.